Telix Pharmaceuticals

Telix reports Third Quarter 2026 Financial Performance

Melbourne (Australia) and Indianapolis, IN (U.S.) | October 21, 2026

Telix provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Q3 2026 Highlights

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Melbourne (Australia), Louvain-la-Neuve (Belgium), Paris (France) and Indianapolis, IN (U.S.) | October 19, 2026

• Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant poten...

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Melbourne (Australia) and Indianapolis, IN (United States) | October 14, 2026

Telix today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to ...

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

Melbourne (Australia) and Indianapolis, IN (United States) | October 9, 2026

Telix today advises that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 p.m. (AEDT).

Institutional investors and analysts are...

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Melbourne (Australia) and Indianapolis, IN (United States) | October 6, 2026

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radi...